Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
(NASDAQ:SILO) SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency t...
Will the new patent affect the company’s upcoming financing plans or potential M&A activity, and how should we position our trades accordingly?
How might this expanded IP portfolio influence market perception, partnership opportunities, and valuation relative to peers?
What impact will the Australian patent grant have on Silo Pharma’s expected timeline and revenue forecasts for the PTSD drug candidate?
11 days ago